Navigating the Dilemma of Patient Eligibility for Wegovy

The shortage of the weight loss medication Wegovy is causing significant challenges for patients and healthcare providers. While the manufacturing shortage will eventually end, many insurance companies deny coverage for weight loss medications, exacerbating the problem. GLP-1 receptor agonists like Wegovy can be effective for weight loss, but access is limited due to insurance restrictions. The author, an endocrinologist, faces the burden of bias against obesity and struggles to provide the best care for patients. The article highlights the complexities of prescribing medications for weight loss and the need for more equitable insurance coverage and access to obesity treatments.